Meet with Kleiner Perkins Caufield Byers
Thursday, March 8, 2012 from 10:00 AM to 11:30 AM (PST)
Meet with Kleiner Perkins Caufield Byers
Thurs. March 8, 2012 | 10:00am-2:00pm, Palo Alto
10:00am - 10:30am: Registration & Networking
10:30am - 11:30am: Presentation and Q&A
11:30am - 2:00pm: One-on-One Meetings*
*Apply by submitting your executive summary
Wilson Sonsini Goodrich & Rosati
650 Page Mill Road
Palo Alto, California 94304
KPCB’s seed investments empower entrepreneurs to create novel new businesses by coupling initial capital with access to our proven team of company builders. KPCB seed investments typically range from $100,000 to $1 million.
KPCB’s early-stage investments recognize a great new company in the making. KPCB supports vision and passion with a team of partners who are some of the most business-savvy people around. Investments at this stage typically range from $1 million to $10 million to help your business achieve its goals.
Our growth-stage investments provide ramp-up funding for innovators who have shown solid market potential. KPCB looks to partner with breakout companies on the fast track to success, typically investing between $10 million to $75 million to help accelerate business momentum. Join us for a one-hour presentation on how entrepreneurs and startups can work directly with KPCB and become part of their dynamic portfolio.
If you would like a one-on-one meeting with KPCB please apply by sending your executive summary to email@example.com. You will be notified by the EBC if you were chosen for a meeting. Once chosen, you may bring 1-3 members of your team to the meeting based upon the pricing below. For EBC Clients, this service is FREE. To become an EBC Client please contact firstname.lastname@example.org.
- Application fee: FREE
- For one member of your team: $75
- For two members of your team: $100
- For three members of your team: $175
Brook Porter joined Kleiner Perkins Caufield & Byers in 2010 as a partner on the greentech team. His focus is on innovative low-carbon solutions to transportation, chemicals and power generation, as well as on energy storage. Before joining KPCB, Brook had worked in renewable energy for more than a decade, during which time he co-founded multiple companies. His most recent role was as chief operating officer of Primafuel, a biofuel technology company recognized by the World Economic Forum in 2008 as a technology pioneer.
Wen Hsieh is a partner with Kleiner Perkins Caufield & Byers U.S. He is also a Managing Partner of KPCB China and leads the Greentech practice there. Since joining the firm in 2006, he has focused on early-stage investments and incubations in green technologies, such as energy storage, fuel cells, renewable fuels and chemicals, and solar PV, as well as disruptive semiconductor innovations. Wen works closely with the teams at Alta Devices, Amprius, Bloom Energy, Crossbar, Mcube, PVNext, Solexel, Spatial Photonics and SuVolta as a board director or observer
David Wells joined Kleiner Perkins Caufield & Byers in 2006 as a partner in the firm’s greentech practice. David builds relationships with scientists, entrepreneurs and technologists, creating knowledge maps and sourcing investment opportunities across the entire greentech landscape with a focus on disruptive order-of-magnitude and tipping-point innovations in the physical sciences. He has helped bring many ventures through the KPCB investment process, including due diligence, investment structuring, team building and goal setting for companies including Aquion Energy, FloDesign Wind Turbine, Modular Wind Energy, Primus Power, Siluria Technologies, Solidia Technologies and several ventures still in stealth stage.
When & Where
Environmental Business Cluster, powered by Prescience International
Prescience International, which operated the Environmental Business Cluster events, has merged with Johnson & Johson. To view our upcoming events, please visit our new Eventbrite page: http://www.eventbrite.com/org/2487775374?s=11857492.
Dear colleagues and friends,
Having been a patient facing a death sentence, I discovered my passion, my purpose in life was to improve the experience and the outcomes for future patients. I set out to impact the healthcare system by creating new models of innovation so the industry might be as advanced and as revered as the tech industry. By establishing innovation centers such as the San Jose BioCenter, the Environmental Business Cluster and Janssen Labs, and educational programs like the UC Berkeley BioExec Institute, we have helped scientists and entrepreneurs deliver real solutions to real patients and we have fostered a networked community that is creating new lifelines for future patients. I never imagined the impact and reach we could have, and yet, it was only scratching the surface.
I've always felt we needed the partnership of global corporations to leverage their resources, infrastructure and influence to catalyze genuine change in the industry. In collaborating with Johnson & Johnson over the past three years, first on Janssen Labs and most recently with Johnson & Johnson's Innovation Centers, we have found a partner who is just as passionate as we are about patients, their families and the innovators who are dedicated to bringing about transformational healthcare products.
It is with great excitement that I announce Prescience is joining forces with J&J, where we will be dedicated to expanding our impact in global innovation hotspots. As Head of Janssen Labs, I will be reporting directly to Diego Miralles, Global Head, Innovation, Janssen Pharmaceuticals. In this new role, I along with the Prescience team members, will expand J&J's external R&D engine; adding capital efficient infrastructure, high impact services, technical and funding programs and strong networks to provide unparalleled access and engagement with entrepreneurial communities around the globe. We will also continue to support the growth of the Johnson & Johnson Innovation Centers and the development of critical services to support early stage company growth.
We look forward to continue to partner with you as we foster a new era in healthcare solutions where people, ideas, and technologies intersect; where we have an open exchange of ideas and collaboration; where we build custom solutions for the right opportunities; where we create new experiences and outcomes for patients.
Together we can transform patient care and build a healthier future.
Founder & CEO, Prescience International
Head of Janssen Labs